Cita APA (7a ed.)

Raskob, G. E., Spyropoulos, A. C., Spiro, T. E., Lu, W., Yuan, Z., Levitan, B., . . . Barnathan, E. S. (2021). Benefit–Risk of Rivaroxaban for Extended Thromboprophylaxis After Hospitalization for Medical Illness: Pooled Analysis From MAGELLAN and MARINER. Wiley.

Cita Chicago Style (17a ed.)

Raskob, Gary E., Alex C. Spyropoulos, Theodore E. Spiro, Wentao Lu, Zhong Yuan, Bennett Levitan, Eunyoung Suh, y Elliot S. Barnathan. Benefit–Risk of Rivaroxaban for Extended Thromboprophylaxis After Hospitalization for Medical Illness: Pooled Analysis From MAGELLAN and MARINER. Wiley, 2021.

Cita MLA (8a ed.)

Raskob, Gary E., et al. Benefit–Risk of Rivaroxaban for Extended Thromboprophylaxis After Hospitalization for Medical Illness: Pooled Analysis From MAGELLAN and MARINER. Wiley, 2021.

Precaución: Estas citas no son 100% exactas.